<DOC>
	<DOCNO>NCT01615393</DOCNO>
	<brief_summary>This prospective , randomize , single-blind , cross-over study compare bioavailability Copegus ( ribavirin ) administer tablet ribavirin administer capsule healthy volunteer . Volunteers randomize receive single dose 400 mg ribavirin either capsule tablet ; washout phase volunteer crossed-over treatment . The anticipated time study treatment 10 day .</brief_summary>
	<brief_title>A Study Compare Bioavailability Copegus VilonaÂ® Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Adult healthy volunteer , 18 55 year age Clinically healthy confirm medical history , physical examination , electrocardiogram , thorax teleradiography routine clinical laboratory measurement Body mass index 18 28 kg/m2 Negative test drug abuse History presence clinically significant condition might interfere pharmacokinetics study drug Volunteers require comedications study Exposure agent know inducer inhibitor hepatic enzymatic system within 30 day prior study start Having take medication clearance period seven halflife study start Hospitalization significant illness 30 day study start Having receive investigational drug within 90 day prior study start</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>